• Explore /
  • Poster
  • / Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).

Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).

Abstract Video & Slides Poster

Authors

Lisa Carey

Lisa A. Carey

University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Lisa A. Carey , Delphine Loirat , Kevin Punie , Aditya Bardia , Veronique Dieras , Florence Dalenc , Jennifer Robinson Diamond , Christel Fontaine , Grace Wang , Hope S. Rugo , Sara A. Hurvitz , Kevin Kalinsky , Joyce O'Shaughnessy , Sibylle Loibl , Luca Gianni , Martine J. Piccart-Gebhart , Quan Hong , Martin Sebastian Olivo , Loretta Itri , Javier Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02574455

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1080)

DOI

10.1200/JCO.2021.39.15_suppl.1080

Abstract #

1080

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Aditya Bardia

First Author: Joyce O'Shaughnessy

First Author: Frederik Marmé

First Author: Eric P. Winer